Please use this identifier to cite or link to this item:
http://hdl.handle.net/11452/26033
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.date.accessioned | 2022-04-25T08:39:04Z | - |
dc.date.available | 2022-04-25T08:39:04Z | - |
dc.date.issued | 2012 | - |
dc.identifier.citation | Bekar, A. vd. (2012). "Effect of reoperation on survival of patients with glioblastoma". Journal of Neurological Sciences-Turkish, 29(1), 110-116. | tr_TR |
dc.identifier.issn | 1302-1664 | - |
dc.identifier.uri | http://hdl.handle.net/11452/26033 | - |
dc.description.abstract | Objective: Surgical resection is the most important part of glioblastoma treatment. The objective of this study was to determine the effect of reoperation on survival of patients with glioblastoma. Methods: Records of the glioblastoma patients operated between 2001 and 2010 by the senior author were analyzed retrospectively. Comparisons were made between patients who received ( Reoperation group, n=50) and who did not receive (Monooperation group, n=111) reoperation with regard to age, gender, tumor localization, number of operations and length of survival. Results: No significant difference was found between two groups in terms of age, gender, and tumor localization. Mean follow-up duration was 12.7 months (range: 1-96 month). Mean lengths of survival after the first operation were 26.7 +/- 4.0 months and 12.2 +/- 1.6 months in the reoperation and monooperation groups, respectively (p<0.001). Regression analysis revealed that reoperation was the only prognostic factor determining the survival in recurrent malignant glial tumors. Moreover, surgical site was shown to affect survival; rate of mortality in patients operated on temporal side was statistically greater than that in patients operated on parietal side (p=0.01). Conclusion: Despite modern treatment strategies, reoperation is still the most important factor determining the length of survival in recurrent glioblastoma. | en_US |
dc.description.abstract | Cerrahi rezeksiyon glioblastoma tedavisinin en önemli kısmını oluşturmaktadır. Bu çalışmanın amacı reoperasyonun glioblastomalı hastaların sağkalımı üzerine etkisini belirlemektir. Araçlar: 2001- 2010 yılları arasında aynı cerrah tarafından opere edilen glioblastoma hastalarının dosyaları retrospektif olarak incelendi. Birden fazla defa opere edilen (reoperasyon grubu, n=50) ve bir kez opere edilen (monooperasyon grubu, n=111) hastalar yaş, cinsiyet, tümör lokalizasyonu, operasyon sayısı ve sağkalım süresi açısından karşılaştırıldı. Sonuçlar: Gruplar arasında yaş, cinsiyet, tümör lokalizasyonu açısından anlamlı farklılık saptanmadı. Ortalama takip süresi 12.7 ay (1-96 ay); ilk operasyondan sonra ortalama sağkalım süresi reoperasyon grubunda 26.7 ±4.0 ay, monooperasyon grubunda 12.2 ±1.6 ay (p<0.001) idi. Regresyon analizine göre tekrarlayan malign glial tümörlerde sağkalımı belirleyen tek prognostik faktör reoperasyon idi. Cerrahi yapılan bölgenin sağkalıma etkisi olduğu gösterildi. Temporal bölgeden opere olan hastalarda mortalite oranı parietal bölgeden opere olanlardan anlamlı olarak yüksek (p=0.01) idi. Modern tedavi stratejilerine rağmen tekrarlayan glioblastomalı hastalarda sağkalım süresini belirleyen en önemli faktör reoperasyondur. | tr_TR |
dc.language.iso | en | en_US |
dc.publisher | Ege Üniversitesi Tıp Fakültesi | tr_TR |
dc.rights | info:eu-repo/semantics/openAccess | en_US |
dc.rights | Atıf Gayri Ticari Türetilemez 4.0 Uluslararası | tr_TR |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
dc.subject | Neurosciences & neurology | en_US |
dc.subject | Glioblastoma | en_US |
dc.subject | Reoperation | en_US |
dc.subject | Survival | en_US |
dc.subject | Prognostic-factors | en_US |
dc.subject | Malignant gliomas | en_US |
dc.subject | Cytoreductive surgery | en_US |
dc.subject | Adjuvant temozolomide | en_US |
dc.subject | Surgical resection | en_US |
dc.subject | Grade glioma | en_US |
dc.subject | Multiforme | en_US |
dc.subject | Recurrent | en_US |
dc.subject | Extent | en_US |
dc.subject | Outcomes | en_US |
dc.subject | Glioblastoma | tr_TR |
dc.subject | Reoperasyon | tr_TR |
dc.subject | Sağkalım | tr_TR |
dc.title | Effect of reoperation on survival of patients with glioblastoma | en_US |
dc.title.alternative | Tekrarlayan ameliyatların glioblastoma hastalarında sağkalıma etkisi | en_US |
dc.type | Article | en_US |
dc.identifier.wos | 000304324800012 | tr_TR |
dc.identifier.scopus | 2-s2.0-84858723886 | tr_TR |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi | tr_TR |
dc.contributor.department | Uludağ Üniversitesi/Tıp Fakültesi/Nöroşirürji Anabilim Dalı. | tr_TR |
dc.contributor.department | Uludağ Üniversitesi/Tıp Fakültesi/Patoloji Anabilim Dalı. | tr_TR |
dc.contributor.orcid | 0000-0001-5472-9065 | tr_TR |
dc.identifier.startpage | 110 | tr_TR |
dc.identifier.endpage | 116 | tr_TR |
dc.identifier.volume | 29 | tr_TR |
dc.identifier.issue | 1 | tr_TR |
dc.relation.journal | Journal of Neurological Sciences-Turkish | en_US |
dc.contributor.buuauthor | Bekar, Ahmet | - |
dc.contributor.buuauthor | Taşkapılıoğlu, Mevlüt Özgür | - |
dc.contributor.buuauthor | Güler, Tuğba Morali | - |
dc.contributor.buuauthor | Aktaş, Ulaş | - |
dc.contributor.buuauthor | Tolunay, Şahsine | - |
dc.contributor.researcherid | AAW-5254-2020 | tr_TR |
dc.contributor.researcherid | ABB-8161-2020 | tr_TR |
dc.contributor.researcherid | AAI-1612-2021 | tr_TR |
dc.indexed.trdizin | TrDizin | en_US |
dc.subject.wos | Neurosciences | en_US |
dc.indexed.wos | SCIE | en_US |
dc.indexed.scopus | Scopus | en_US |
dc.contributor.scopusid | 6603677218 | tr_TR |
dc.contributor.scopusid | 55123171000 | tr_TR |
dc.contributor.scopusid | 55123170500 | tr_TR |
dc.contributor.scopusid | 55122917500 | tr_TR |
dc.contributor.scopusid | 6602604390 | tr_TR |
dc.subject.scopus | Re-Irradiation; Temozolomide; Glioblastoma | en_US |
dc.subject.emtree | Temozolomide | en_US |
dc.subject.emtree | Adult | en_US |
dc.subject.emtree | Age | en_US |
dc.subject.emtree | Aged | en_US |
dc.subject.emtree | Article | en_US |
dc.subject.emtree | Cancer recurrence | en_US |
dc.subject.emtree | Cancer survival | en_US |
dc.subject.emtree | Female | en_US |
dc.subject.emtree | Follow up | en_US |
dc.subject.emtree | Gender | en_US |
dc.subject.emtree | Glioblastoma | en_US |
dc.subject.emtree | Glioma | en_US |
dc.subject.emtree | Human | en_US |
dc.subject.emtree | Major clinical study | en_US |
dc.subject.emtree | Male | en_US |
dc.subject.emtree | Medical record review | en_US |
dc.subject.emtree | Prognosis | en_US |
dc.subject.emtree | Reoperation | en_US |
dc.subject.emtree | Retrospective study | en_US |
dc.subject.emtree | Surgical mortality | en_US |
dc.subject.emtree | Tumor localization | en_US |
Appears in Collections: | Scopus TrDizin Web of Science |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Bekar_vd_2012.pdf | 207.16 kB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License